[Quizartinib associated to chemotherapy in newly diagnosed patients with FLT3-ITD positive acute myeloid leukemia]

Bull Cancer. 2024 Sep;111(9):793-794. doi: 10.1016/j.bulcan.2024.02.012. Epub 2024 Jun 13.

[Article in French]

Authors

Sabrina Barrière¹, Aurélie Ravinet²

Affiliations

¹ CHU de Clermont-Ferrand, service d'hématologie clinique et de thérapie cellulaire, 1, rue Lucie-et Raymond-Aubrac, 63100 Clermont-Ferrand, France. Electronic address: [email protected].
² CHU de Clermont-Ferrand, service d'hématologie clinique et de thérapie cellulaire, 1, rue Lucie-et Raymond-Aubrac, 63100 Clermont-Ferrand, France.

PMID: 38876894
DOI: 10.1016/j.bulcan.2024.02.012

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Benzothiazoles* / adverse effects
Benzothiazoles* / therapeutic use
Female
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Male
Middle Aged
Phenylurea Compounds* / adverse effects
Phenylurea Compounds* / therapeutic use
Tandem Repeat Sequences
fms-Like Tyrosine Kinase 3* / genetics

Substances

fms-Like Tyrosine Kinase 3
quizartinib
Phenylurea Compounds
FLT3 protein, human
Benzothiazoles
Antineoplastic Agents